End-of-day quote
NORDIC GROWTH MARKET
06:00:00 2024-05-30 pm EDT
|
5-day change
|
1st Jan Change
|
0.0546
DKK
|
+29.38%
|
|
-7.46%
|
+82.00%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
---|
Capitalization
1 |
66.75
|
175.2
|
37.06
|
Enterprise Value (EV)
1 |
45.61
|
167.5
|
26.31
|
P/E ratio
|
-6.71
x
|
-12.7
x
|
-2.31
x
|
Yield
|
-
|
-
|
-
|
Capitalization / Revenue
|
-13.8
x
|
200
x
|
5.15
x
|
EV / Revenue
|
-9.44
x
|
192
x
|
3.66
x
|
EV / EBITDA
|
-7.9
x
|
-12.3
x
|
-1.85
x
|
EV / FCF
|
-1,584,675
x
|
-5,222,178
x
|
-1,496,042
x
|
FCF Yield
|
-0%
|
-0%
|
-0%
|
Price to Book
|
1.51
x
|
3.28
x
|
0.59
x
|
Nbr of stocks (in thousands)
|
20,731
|
26,551
|
65,015
|
Reference price
2 |
3.220
|
6.600
|
0.5700
|
Announcement Date
|
4/7/21
|
4/12/22
|
5/12/23
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
---|
Net sales
1 |
-0.4218
|
-4.83
|
0.874
|
7.189
|
EBITDA
1 |
-0.6189
|
-5.776
|
-13.62
|
-14.19
|
EBIT
1 |
-0.6268
|
-5.87
|
-14.51
|
-16.42
|
Operating Margin
|
148.6%
|
121.55%
|
-1,659.95%
|
-228.38%
|
Earnings before Tax (EBT)
1 |
-0.6384
|
-5.986
|
-15.18
|
-18.25
|
Net income
1 |
-0.4998
|
-4.255
|
-11.75
|
-16.06
|
Net margin
|
118.5%
|
88.09%
|
-1,344.39%
|
-223.45%
|
EPS
|
-
|
-0.4801
|
-0.5200
|
-0.2471
|
Free Cash Flow
|
-
|
-28.78
|
-32.07
|
-17.58
|
FCF margin
|
-
|
595.93%
|
-3,669.89%
|
-244.6%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/7/21
|
4/7/21
|
4/12/22
|
5/12/23
|
Fiscal Period: December |
2022 Q1
|
2023 Q1
|
---|
Net sales
1 |
1.266
|
0.62
|
EBITDA
|
-
|
-
|
EBIT
|
-
|
-
|
Operating Margin
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
Net income
|
-
|
-
|
Net margin
|
-
|
-
|
EPS
2 |
-0.0100
|
-0.0500
|
Dividend per Share
|
-
|
-
|
Announcement Date
|
5/18/22
|
5/31/23
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
Net Cash position
1 |
0.18
|
21.1
|
7.74
|
10.8
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-28.8
|
-32.1
|
-17.6
|
ROE (net income / shareholders' equity)
|
-
|
-19.5%
|
-24.1%
|
-27.7%
|
ROA (Net income/ Total Assets)
|
-
|
-14.4%
|
-15.3%
|
-14.4%
|
Assets
1 |
-
|
29.58
|
76.81
|
111.7
|
Book Value Per Share
|
-
|
2.140
|
2.010
|
0.9700
|
Cash Flow per Share
|
-
|
1.030
|
0.2900
|
0.1700
|
Capex
1 |
0.06
|
4.02
|
6.37
|
1.01
|
Capex / Sales
|
-14.62%
|
-83.14%
|
728.83%
|
13.99%
|
Announcement Date
|
4/7/21
|
4/7/21
|
4/12/22
|
5/12/23
|
|
1st Jan change
|
Capi.
|
---|
| +82.00% | 1.32M | | +11.91% | 118B | | +11.60% | 106B | | -4.68% | 24.28B | | -0.09% | 21.96B | | -9.42% | 18.16B | | -42.12% | 16.37B | | -17.47% | 15.56B | | +2.77% | 13.63B | | +34.58% | 12.27B |
Bio Therapeutic Drugs
|